Related references
Note: Only part of the references are listed.BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis
Tommy Nyberg et al.
BRITISH JOURNAL OF CANCER (2022)
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
Shuai Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) a multicentre, open-label, phase 2 trial
Matthew R. Smith et al.
LANCET ONCOLOGY (2022)
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Michael S. Leapman et al.
JAMA ONCOLOGY (2022)
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis
Pawel Rajwa et al.
EUROPEAN UROLOGY (2022)
Germline testing and genetic counselling in prostate cancer
Jessica Russo et al.
NATURE REVIEWS UROLOGY (2022)
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
Yukihide Momozawa et al.
JAMA ONCOLOGY (2022)
Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis
Tatsushi Kawada et al.
EUROPEAN UROLOGY ONCOLOGY (2022)
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
Axel S. Merseburger et al.
EUROPEAN UROLOGY (2021)
Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations
N. Shore et al.
JOURNAL OF UROLOGY (2021)
Reimagining prostate cancer screening: the IMPACT of germline mutations
Giorgio Gandaglia et al.
LANCET ONCOLOGY (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2021)
AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
Dana E. Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis
Pawel Rajwa et al.
JOURNAL OF UROLOGY (2021)
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography The IP1-PROSTAGRAM Study
David Eldred-Evans et al.
JAMA ONCOLOGY (2021)
Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis
Pawel Rajwa et al.
EUROPEAN UROLOGY (2021)
Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer
Jacob E. Berchuck et al.
EUROPEAN UROLOGY (2021)
Prostate cancer and PARP inhibitors: progress and challenges
Diego Teyssonneau et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time
Roderick Clark et al.
EUROPEAN UROLOGY FOCUS (2021)
Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021
Hendrik Van Poppel et al.
EUROPEAN UROLOGY (2021)
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
Tobias Nordstrom et al.
LANCET ONCOLOGY (2021)
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Martin Eklund et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Barriers and facilitators of germline genetic evaluation for prostate cancer
Stacy Loeb et al.
PROSTATE (2021)
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis
Elio Mazzone et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality
Alice Boileve et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Stacy Loeb et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Tommy Nyberg et al.
EUROPEAN UROLOGY (2020)
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
Niranjan J. Sathianathen et al.
EUROPEAN UROLOGY (2020)
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
David E. Neal et al.
EUROPEAN UROLOGY (2020)
Germline and somatic DNA repair gene alterations in prostate cancer
Marc A. Dall'Era et al.
CANCER (2020)
Short-Term Outcomes of Active Surveillance for Low Risk Prostate Cancer among Men with Germline DNA Repair Gene Mutations
Daniel Halstuch et al.
JOURNAL OF UROLOGY (2020)
Reconsidering Prostate Cancer Mortality - The Future of PSA Screening
H. Gilbert Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer
Tal Hadar et al.
JAMA ONCOLOGY (2020)
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Veda N. Giri et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
Z. Zumsteg et al.
ANNALS OF ONCOLOGY (2020)
Risk Stratification of Prostate Cancer According to PI-RADS® Version 2 Categories: Meta-Analysis for Prospective Studies
Kye Jin Park et al.
JOURNAL OF UROLOGY (2020)
Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment
Michael T. Schweizer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability
Matthew R. Cooperberg et al.
JAMA ONCOLOGY (2020)
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
Carlo Messina et al.
JOURNAL OF ONCOLOGY (2020)
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials
Emmanuel S. Antonarakis et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening
N. Segal et al.
ANNALS OF ONCOLOGY (2020)
External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis
Marco Moschini et al.
EUROPEAN UROLOGY (2019)
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
Jonas Hugosson et al.
EUROPEAN UROLOGY (2019)
Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?
Marc Dall'era et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The influence of BRCA2 mutation on localized prostate cancer
Renea A. Taylor et al.
NATURE REVIEWS UROLOGY (2019)
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis
Mok Oh et al.
PROSTATE (2019)
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
Piper Nicolosi et al.
JAMA ONCOLOGY (2019)
Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Elizabeth C. Page et al.
EUROPEAN UROLOGY (2019)
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial
Paul F. Pinsky et al.
BJU INTERNATIONAL (2019)
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
H. Ballentine Carter et al.
EUROPEAN UROLOGY (2019)
Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank
Noura S. Abul-Husn et al.
GENOME MEDICINE (2019)
Prostate-Specific Antigen-Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive Services Task Force
Joshua J. Fenton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality The CAP Randomized Clinical Trial
Richard M. Martin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
V Kasivisvanathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer
Pedro Isaacsson Velho et al.
PROSTATE (2018)
Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis
Mohannad A. Awad et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort
Roy Mano et al.
JAMA ONCOLOGY (2018)
Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators
Ben Van Calster et al.
EUROPEAN UROLOGY (2018)
Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States
Scott P. Kelly et al.
EUROPEAN UROLOGY FOCUS (2018)
Extended Mortality Results for Prostate Cancer Screening in the PLCO Trial With Median Follow-Up of 15 Years
Paul F. Pinsky et al.
CANCER (2017)
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na et al.
EUROPEAN UROLOGY (2017)
PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING
Donald F. Gleason et al.
JOURNAL OF UROLOGY (2017)
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Timothy J. Wilt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Definition of Grading Patterns and Proposal for a New Grading System
Jonathan I. Epstein et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
F. C. Hamdy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers
Yael Laitman et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
Elena Castro et al.
EUROPEAN UROLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian
Jacqueline Mersch et al.
CANCER (2015)
Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial
Paul F. Pinsky et al.
BJU INTERNATIONAL (2014)
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Elizabeth K. Bancroft et al.
EUROPEAN UROLOGY (2014)
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schroder et al.
LANCET (2014)
Systematic Review of Complications of Prostate Biopsy
Stacy Loeb et al.
EUROPEAN UROLOGY (2013)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial
Leonard P. Bokhorst et al.
BJU INTERNATIONAL (2012)
Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)
Fritz H. Schroder et al.
EUROPEAN UROLOGY (2012)
The CAPRA-S Score A Straightforward Tool for Improved Prediction of Outcomes After Radical Prostatectomy
Matthew R. Cooperberg et al.
CANCER (2011)
Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer
Peter C. Albertsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005
H. Gilbert Welch et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
Phuong L. Mai et al.
PLOS ONE (2009)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
Share Paper
